Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
Roberto Buonaiuto(Scuola Superiore Meridionale), Carmine De Angelis(Baylor College of Medicine), Angela Grieco(University of Naples Federico II), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Aldo Caltavituro(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Letizia Cataldo(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Andrea Botticelli(Sapienza University of Rome), Paolo Chiodini(University of Campania "Luigi Vanvitelli"), Mario Fordellone(University of Campania "Luigi Vanvitelli"), Lorenzo Gerratana(National Cancer Institute), Mario Giuliano(Regione Campania), Alessandra Longobardi(Federico II University Hospital), Matteo Lambertini(Ospedale Policlinico San Martino), Luca Malorni(Azienda Usl Toscana Centro), Antonio Giordano(Harvard University), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmen Criscitiello(University of Milan), Federica P. Mangiacotti(Federico II University Hospital), Martina Pagliuca(Institut Gustave Roussy)
Cited by 7
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer and fertility preservation: international recommendations from an expert meeting
|BMC Medicine|2016|779
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724